Exhibit 10.103
 ***Text Omitted and Filed Separately
with the Securities and Exchange Commission.
Confidential Treatment Requested
Under 17 C.F.R. Sections 200.80(b)(4)
and 240.24b-2.
 RESTATED AGREEMENT
 between
 GEN-PROBE INCORPORATED
 and
 NOVARTIS VACCINES AND DIAGNOSTICS, INC.
 Dated as of July 24, 2009




---



##### 



RESTATED AGREEMENT
 Agreement Effective Date Gen-Probe Novartis
    inter alia
 1998 Agreement
   1




---



##### 



ARTICLE 1
 DEFINITIONS
  Affiliate
 Ancillary Product
 Applicable Purchase Price
  plus
  Calendar Year
    
    Applicable Percentage2009
    
    
    44
    %2010
    
    
    46
    %2011
    
    
    46
    %2012
    
    
    47
    %2013
    
    
    47
    %2014
    
    
    48
    %2015 and all subsequent years
during the Blood Screening Term
    
    
    50
    %
 2




---



##### 



plus
  provided however
 provided
  Blood Screening Assays
 Blood Screening Field
 Blood Screening Instruments
 3




---



##### 



Blood Screening Term
 CBER
 Change in Control unless
 Clinical Diagnostic Field
 Commercially Reasonable Efforts
   Competitive Probe Assay
 Component Instruments
 4




---



##### 



Confidential Information
  Customer
 Development Costs
 Development Program
 ESAS Instrument
 5




---



##### 



ESAS 2 Instrument
 FDA
 First Commercial Sale
 Forecast
 Gen-Probe Copyrights
 Gen-Probe IP Rights
 Gen-Probe Know-How
 Gen-Probe Marks
 Gen-Probe Patent Rights
 6




---



##### 



HCV Blood Screening Assays
 HCV
 HIV-1
  Manufacturing Cost
 7




---



##### 



Net Sales Seller
 Combination Product
  8




---



##### 



Non-HCV Blood Screening Assays
 Novartis Copyrights
 Novartis Know-How
 Novartis Marks
 Novartis Patent Rights
 Novartis IP Rights
 9




---



##### 



Panther Instrument
 Person
 Product
 Purchase Order
 Registration Trial
 Roche Promoter-Primer Patent Claims
 Spare Part
 Supervisory Board
 Territory
 ***Confidential Treatment Requested
 10




---



##### 



Third Party
 Tigris Instrument
 TMA Assay
 Transfer Price
      ***Confidential Treatment Requested
 11
         Ultrio Assay Product
 Ultrio Plus Assay Product
 Valid Claim
 WNV Assay Product
 ARTICLE 2
 REPRESENTATIONS AND WARRANTIES
 By Each Party
 ***Confidential Treatment Requested
 12




---



##### 



Corporate Existence and Power
 Authorization and Enforcement of Obligations
 Consents
 No Conflict
 DISCLAIMER OF WARRANTIES
 13




---



##### 



ARTICLE 3
 BLOOD SCREENING PRODUCTS
 Blood Screening Assays; Blood Screening Instruments
 Current Products
 New Product Development.
    14




---



##### 



Development Programs
 Establishment
 Responsibilities
 Conduct of Development
 Subcontracts provided, however
 15




---



##### 



Funding
 1 2
     16




---



##### 



Records and Reports for Development Programs
 Records
 Inspection of Records
 Development Reports and Information
 Regulatory Matters
   17




---



##### 



Initiation of Companion Diagnostic Program
 Manufacturing
  Step-In Manufacturing Rights
 Assays provided, however
 Instruments
 ***Confidential Treatment Requested
 18




---



##### 



Commercialization
  19




---



##### 



New Market Entry
  20




---



##### 



Licenses
    Gen-Probes Rights in Japan in the Clinical Diagnostic Field HBV Discriminatory Assay
 Immunity Under Roche Promoter-Primer Patent Claims
 ***Confidential Treatment Requested
 21




---



##### 



Noncompetition
    Other Blood Screening Instruments
 ***Confidential Treatment Requested
 22




---



##### 



New Technology; Alternative Technology
 New Technology New Technology
 Impacted Field Impacted
Products
 23




---



##### 



Alternative Technology Identified by Gen-Probe Alternative Technology
 Alternative Technology Identified by Novartis (Option 1) without (Option 2)
 Option 1
 ***Confidential Treatment Requested
 24




---



##### 



Option 2 Option 2
  ***Confidential Treatment Requested
 25




---



##### 



ARTICLE 4
 SUPERVISORY BOARD
 Supervisory Board
 Generally; Composition
 Meetings
 Actions
 Reports
 26




---



##### 



Operating Committee
 Purpose Operating Committee
 Activities
 Composition.
 Operation
 ARTICLE 5
 SUPPLY TERMS
 Manufacture and Sale
 Manufacturing Practices
 Specifications
 27




---



##### 



Audit
 Certificates of Analysis
 Quality Control Information
 Blood Screening Assays: Forecasts and Orders; Purchase Obligation; Purchase Orders;
Inventory; Supply Obligation; Delivery and Acceptance
 Blood Screening Assays Forecasts
     28




---



##### 



st nd rd th th th th th th th th th th st th th th th th th th th
 th not down st th
 29




---



##### 



th th th th
   Blood Screening Assays Purchase Obligation.
    30




---



##### 



Blood Screening Assays Purchase Orders
 Schedule 5.3.3
    31




---



##### 



Blood Screening Assays Inventory
    Blood Screening Assays Supply Obligation
  32




---



##### 



Blood Screening Assays Delivery and Acceptance
   Blood Screening Instruments: Forecasts; Purchase Orders and Purchase Obligation;
Supply Obligation; Shipping and Delivery; Engineering Change Notification
 Blood Screening Instrument Forecasts
 33




---



##### 



Tigris Instrument Allocation Plan
  34




---



##### 



Blood Screening Instruments Purchase Orders and Purchase Obligation
 Tigris Instruments Tigris Instrument Purchase Orders
    Component Instruments Component Instrument Purchase Orders
  35




---



##### 



Spare Parts Spare Parts Purchase Orders
  36




---



##### 



Emergency Purchase Orders Emergency Purchase Order
 37




---



##### 



Blood Screening Instruments Supply Obligation
 Tigris Instruments
     Component Instruments
 Spare Parts
  38




---



##### 



Five Year Support and Parts Availability
 Blood Screening Instruments Shipping and Delivery
 Tigris Instruments
 39




---



##### 



Component Instruments
 Spare Parts
 Blood Screening Instruments Engineering Change Notification
 Tigris Instruments
 Component Instruments
 40




---



##### 



Spare Parts
 Packaging
 Rejection and Cure
 Blood Screening Assays
 Blood Screening Instruments
 LIMITATION OF LIABILITY
 41




---



##### 



Warranty
 LIMITATION OF LIABILITY
 Complaint Resolution
 Independent Purchaser Status
 Non-Commercial Products
 Internal Commercial Use
 42




---



##### 



ARTICLE 6
 PAYMENTS AND REPORTS
 Compensation
 Compensation to Gen-Probe for Blood Screening Assays
 Transfer Price
 Applicable Purchase Price
 Compensation to Gen-Probe for Blood Screening Instruments
 Transfer Price
 Instrument Sales in the United States and Canada
   43




---



##### 



Instrument Sales Outside the United States and Canada
 Reagent Rentals Outside the United States and Canada
 Reimbursement of Development Costs for FEP and RAS Components of eSAS 2
Instrument
 Compensation to Gen-Probe for Ancillary Products
 Transfer Price; Shipping
 Additional Compensation
 44




---



##### 



Gen-Probes Agreement To Contribute To HIV Patent Payments
         ***Confidential Treatment Requested
 45




---



##### 



Invoicing
 Reports
 ***Confidential Treatment Requested
 46




---



##### 



Reagent Rental Reports
 Exchange Rates
 Audits
 Requesting Party Responding Party
   47




---



##### 



Payment Method
 Exchange Control
 Sales and Use Taxes
 Withholding Taxes
 Late Payments
 ARTICLE 7
 CONFIDENTIALITY
 Confidential Information Receiving Party Disclosing Party
 48




---



##### 



Terms of this Agreement
 Permitted Disclosures
 ARTICLE 8
 INVENTIONS AND INTELLECTUAL PROPERTY RIGHTS
 Ownership of Inventions
 Inventions Gen-Probe Inventions Novartis Inventions Joint Inventions
 49




---



##### 



***Confidential Treatment Requested
 50




---



##### 



***Confidential Treatment Requested
 51




---



##### 



52




---



##### 



both provided
   provided
    53




---



##### 



54




---



##### 



Patent Rights
 Copyrights
 Gen-Probe Copyrights and Novartis Copyrights
 Copyright Protection
 55




---



##### 



Trademarks
 Gen-Probe Marks and Novartis Marks
 Other Technology Rights
 Third Party Technology
 Stanford Agreement
 56




---



##### 



Teknika Agreement
 Continuation of Rights
 ARTICLE 9
 INDEMNIFICATION AND INSURANCE
 Indemnity
 By Gen-Probe
 By Novartis
 57




---



##### 



Procedure Indemnitee Indemnitor provided however
 Insurance
 ARTICLE 10
 TERM AND TERMINATION
 Expiration
 Termination
 Breach
 58




---



##### 



Voluntary Bankruptcy
 Involuntary Bankruptcy
 Effect of Expiration and Termination
 59




---



##### 



ARTICLE 11
 ARBITRATION
 Executive Mediation
 Arbitration Procedure
 Review
 60




---



##### 



ARTICLE 12
 MISCELLANEOUS
 Notices
 If to Gen-Probe:
    
    Gen-Probe Incorporated10210 Genetic Center DriveSan Diego, California 92121Attention: President andChief Executive OfficerIf to Novartis:
    
    Novartis Vaccines and Diagnostics, Inc.4560 Horton StreetEmeryville, California 94608Attention: President, Diagnostics
 Force Majeure
 61




---



##### 



Assignment
 provided however
   Severability
 62




---



##### 



Applicable Law
 Entire Agreement
 Prior Agreements Claims
       63




---



##### 



Amendment
 Expenses and Attorneys Fees
 Independent Contractors
 Waiver
 Drafting Party
 64




---



##### 



Third Parties
 Affiliates
 Counterparts
  GEN-PROBE INCORPORATED
    
    NOVARTIS VACCINES AND DIAGNOSTICS, INC.By
    
    /s/ Carl W. Hull

Carl W. Hull
    
    By
    
    /s/ Peter Maag

Peter MaagPresident & CEO
    
    
    
    President, DiagnosticsJuly 24, 2009
    
    
    
    July 24, 2009
 65




---



##### 



Schedule 1.51
 Transcription-Based Amplification Versions
            ***Confidential Treatment Requested
 1




---



##### 



***Confidential Treatment Requested
 2




---



##### 



Schedule 3.1.6
 Licensed Manufacturers
 Legal
    
    Location ofProduct
    
    Manufacturer
    
    Manufacture
    
    Current DocumentPROCLEIX®
OptivaTM Reagent 
Addition Station (RAS)
    
    Chiron Corporation
    
    Stratec Biomedical
Systems
Germany
    
    CFG, FDA 510(k)
Clearance, EIR
(Chiron), ISO 13485
(Chiron), ISO
9001:2000 (Chiron),
Declaration of
ConformityPROCLEIX®
OptivaTM Front End 
Pipetter (FEP)
    
    Gen Probe Incorp
Incorporated
    
    Stratec Biomedical
Systems
Germany
    
    Certificate of
Exportability, EIR
(Gen-Probe), ISO
13485 (Gen- Probe),
ISO 9001:2000
(Chiron),Declaration
of ConformityPROCLEIX®TIGRIS®
System
    
    Gen-Probe Incorporated
    
    KMC Systems
Incorporated U.S.A.
    
    Certificate of
Exportability, ER
(Gen-Probe), ISO
13485 (Gen- Probe),
ISO 9001:2000
(Chiron),
Declaration of
ConformityPROCLEIX®
Reagent Preparation 
Incubator
    
    Gen-Probe
Incorporated
    
    Barnstead/ Lab- Line
U.S.A.
    
    Certificate of
Exportability, EIR
(Gen-Probe), ISO
13485 (Gen- Probe),
ISO 9001:2000
(Chiron),
Declaration of
ConformityPROCLEIX® System
    
    Gen-Probe
IncorporatedTarget Capture
System
    
    Gen Probe Incorporated
    
    
    
    CFG, FDA
510(k) Clearance,
EIR (Gen-Probe),
ISO 13485 (Gen-
Probe), ISO
9001:2000 (Chiron),
Declaration of
ConformityHC+ Luminometer
    
    Gen-Probe
Incorporated
    
    MGM Instruments
Incorporated
U.S.A.TECAN GENESIS RSP 150/8
    
    Gen-Probe Incorporated
    
    TECAN AG SwitzerlandPanther
    
    Expected to be
Gen-Probe Incorporated
    
    Stratec
Biomedical Systems
Germany
    
    TBD
 1




---



##### 



Schedule 5.3.1(a)
 Labeling Requirements
 Part Number
    
    Description
    
    Label Options301034
    
    PROFICIENCY PANELS
    
    IVD301030
    
    5000T KIT DOMESTIC
    
    IVD301031
    
    1000T KIT DOMESTIC
    
    IVD301027
    
    TMA FLUIDS DOMESTIC
    
    IVD301026
    
    DISCRIMINATORY KIT DOMESTIC
    
    IVD301036
    
    CALIBRATORS DOMESTIC
    
    IVD301038
    
    AUTO DETECT DOMESTIC
    
    IVD301035
    
    CONTROL SET DOMESTIC
    
    IVD301030E
    
    5000T KIT EXPORT
    
    IVD301031E
    
    1000T KIT EXPORT
    
    IVD301026E
    
    DISCRIMINATORY KIT EXPORT
    
    IVD301036E
    
    CALIBRATORS EXPORT
    
    IVD301035E
    
    CONTROL SET EXPORT
    
    IVDTU0018
    
    TTU (1000 Tests) SASTU0022
    
    TTU (1000 Tests) eSAS104578
    
    TTC (1000 Tests)102085
    
    Sealing Cards
 1




---



##### 



Schedule 5.3.3
 Sample Purchase Order
  ***Confidential Treatment Requested
 1




---



##### 



***Confidential Treatment Requested
 2




---



##### 



***Confidential Treatment Requested
 3




---



##### 



***Confidential Treatment Requested
 4




---



##### 



Schedule 6.1.2(e)
 Reimbursement of Development Costs for FEP and RAS Components of eSAS2 Instrument
  Revenues from the FEP Component and RAS Component
 Revenues for Collaboration Combination Products Collaboration Combination Product
 Revenues for Lease, Rental or Placement Programs Program
   FEP Component
 Fully Burdened Manufacturing Costs
 3




---



##### 



Gen-Probe Blood Screening Split
 Gen-Probe Clinical Diagnostic Split
 Novartis Blood Screening Split
 Novartis Clinical Diagnostic Split
 RAS Component
 Instrument Sales; Novartis Sales oft-EP Components and RAS Components
  4




---



##### 



Instrument Sales; Gen-Probe Sales of FEP Components and RAS Components
  Service Revenues
 5




---



##### 



Schedule 8.1.6(e)
 Novartis Corporation Core Technologies
  HUMAN IMMUNODEFICIENCY VIRUS (HIV)
 Title of Invention
    
    Patent/Pub. No.
    
    
    Issue/Pub. Date
    
    
    Priority Date[...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...][...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...]
 HEPATITIS C VIRUS (HCV)
 Title of Invention
    
    Patent/Pub. No.
    
    
    Issue/Pub. Date
    
    
    Priority Date[...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...][...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...][...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...][...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...][...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...][...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...][...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...]
 [...***...]
 Title of Invention
    
    Patent/Pub. No.
    
    
    Issue/Pub. Date
    
    
    Priority Date[...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...]
 ***Confidential Treatment Requested
 1




---



##### 



Title of Invention
    
    Patent/Pub. No.
    
    
    Issue/Pub. Date
    
    
    Priority Date[...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...][...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...][...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...][...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...][...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...][...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...][...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...][...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...][...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...][...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...][...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...][...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...][...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...][...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...][...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...][...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...][...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...][...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...][...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...][...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...][...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...][...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...][...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...][...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...][...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...]
 [...***...]
 Title of Invention
    
    Patent/Pub. No.
    
    
    Issue/Pub. Date
    
    
    Priority Date[...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...][...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...]
 ***Confidential Treatment Requested
 2




---



##### 



Schedule 8.7
 Gen-Probe Incorporated Core Technologies
  A. [...***...]
 Title of Invention
    
    Issue/Pub No
    
    
    Issue/Pub Date
    
    
    Priority Date[...***...]
    
    
    [...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...][...***...]
    
    
    [...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...][...***...]
    
    
    [...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...][...***...]
    
    
    [...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...][...***...]
    
    
    [...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...][...***...]
    
    
    [...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...][...***...]
    
    
    [...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...][...***...]
    
    
    [...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...][...***...]
    
    
    [...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...][...***...]
    
    
    [...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...][...***...]
    
    
    [...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...][...***...]
    
    
    [...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...][...***...]
    
    
    [...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...]
 ***Confidential Treatment Requested
 1




---



##### 



Title of Invention
    
    Issue/Pub No
    
    
    Issue/Pub Date
    
    
    Priority Date[...***...]
    
    
    [...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...][...***...]
    
    
    [...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...][...***...]
    
    
    [...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...][...***...]
    
    
    [...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...][...***...]
    
    
    [...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...][...***...]
    
    
    [...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...]
 B.[...***...]
 [...***...]
    
    
    [...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...][...***...]
    
    
    [...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...][...***...]
    
    
    [...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...][...***...]
    
    
    [...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...][...***...]
    
    
    [...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...][...***...]
    
    
    [...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...][...***...]
    
    
    [...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...][...***...]
    
    
    [...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...][...***...]
    
    
    [...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...]
 C. [...***...]
 [...***...]
 [...***...]
    
    
    [...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...][...***...]
    
    
    [...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...][...***...]
    
    
    [...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...][...***...]
    
    
    [...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...][...***...]
    
    
    [...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...][...***...]
    
    
    [...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...]
 ***Confidential Treatment Requested
 2




---



##### 



D. [...***...]
 [...***...]
    
    
    [...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...]
 E. [...***...]
 [...***...]
    
    
    [...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...][...***...]
    
    
    [...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...][...***...]
    
    
    [...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...][...***...]
    
    
    [...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...]
 F. [...***...]
  [...***...]
    
    
    [...***...]
    
    
    [...***...]
    
    
    
    [...***...]
    
    
    
    [...***...]
 ***Confidential Treatment Requested
 3




---



##### 



Schedule 8.9
 Additional Clauses Relating to the Stanford Agreement and the Teknika Agreement
  Stanford License
       1




---



##### 



2




---



##### 



Teknika Agreement
     3